Positive Phase III data for migraine drug Fremanezumab
Positive results from a Phase III HALO study of fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody investigational treatment for the prevention of migraine, have been announced by Israel-based Teva Pharmaceutical Industries (NYSE: TEVA). In the chronic migraine (CM) study, patients treated with fremanezumab experienced statistically-significant reduction in the number of monthly headache days of …
Positive Phase III data for migraine drug Fremanezumab Read More »